RSPI RespireRx Pharmaceuticals Inc (CE)

Item 7.01. Regulation FD Disclosure.

ResolutionRx, the pharmaceutical cannabinoid business unit of RespireRx Pharmaceuticals Inc. (the “Company”), participated in the 5^th International Cannabinoid-Derived Pharmaceuticals Summit, which took place September 7-8, 2022 in Boston, MA. As an invited guest speaker, Arnold S. Lippa, Ph.D., the Company’s Interim President, Interim Chief Executive Officer, and Chief Scientific Officer presented a talk (“Presentation Materials”) entitled “Drug Re-purposing: A Case Study of Dronabinol”, in which he described the advantages of re-purposing an already FDA approved drug for a new therapeutic indication, using our development program for dronabinol as an example. Dr. Lippa reviewed the clinical and operational programs completed to date and then focused on our new lipid-based nanotechnology formulation for dronabinol that is intended to create a superior approach to administering oral dronabinol as well as extend and solidify our intellectual property base. During the summit, he also participated in meetings with third parties.

The information in this Item 7.01 and the document attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.